SRPT Sarepta Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

SRPT [NASD]

Sarepta Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-8.83	Insider Own	4.90%	Shs Outstand	76.43M	Perf Week	-5.22%
Market Cap	11.36B	Forward P/E	-	EPS next Y	-2.35	Insider Trans	-6.91%	Shs Float	74.25M	Perf Month	21.41%
Income	-655.90M	PEG	-	EPS next Q	-1.60	Inst Own	95.10%	Short Float	15.56%	Perf Quarter	20.78%
Sales	407.50M	P/S	27.88	EPS this Y	-77.80%	Inst Trans	0.36%	Short Ratio	12.05	Perf Half Y	30.28%
Book/sh	14.98	P/B	9.68	EPS next Y	58.10%	ROA	-31.90%	Target Price	192.81	Perf Year	19.11%
Cash/sh	27.71	P/C	5.23	EPS next 5Y	-0.20%	ROE	-64.70%	52W Range	72.05 - 158.80	Perf YTD	12.38%
Dividend	-	P/FCF	42.86	EPS past 5Y	-23.40%	ROI	-47.10%	52W High	-8.68%	Beta	1.87
Dividend %	-	Quick Ratio	7.70	Sales past 5Y	108.10%	Gross Margin	86.00%	52W Low	101.26%	ATR	6.52
Employees	743	Current Ratio	8.30	Sales Q/Q	30.70%	Oper. Margin	-	RSI (14)	58.25	Volatility	3.53% 5.02%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	78.60%	Profit Margin	-	Rel Volume	0.69	Prev Close	149.04
Shortable	Yes	LT Debt/Eq	0.60	Earnings	May 06 AMC	Payout	-	Avg Volume	958.70K	Price	145.01
Recom	1.70	SMA20	1.96%	SMA50	18.92%	SMA200	33.61%	Volume	665,460	Change	-2.70%

Mar-31-20

Initiated

Mizuho

Buy

$183

Nov-01-19

Initiated

Guggenheim

Buy

$183

Aug-21-19

Reiterated

Needham

Buy

$196 → $170

Jul-09-19

Reiterated

Morgan Stanley

Overweight

$165 → $220

Jul-01-19

Reiterated

RBC Capital Mkts

Outperform

$188 → $220

Apr-12-19

Initiated

Evercore ISI

Outperform

Mar-11-19

Reiterated

Credit Suisse

Outperform

$189 → $207

Oct-12-18

Initiated

Bernstein

Outperform

Oct-01-18

Initiated

Cantor Fitzgerald

Overweight

$217

Sep-26-18

Reiterated

RBC Capital Mkts

Outperform

$187 → $200

Sep-14-18

Resumed

BofA/Merrill

Buy

$199

Sep-06-18

Initiated

Credit Suisse

Outperform

$178

Aug-01-18

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Jun-21-18

Reiterated

Robert W. Baird

Outperform

$120 → $202

Jun-20-18

Reiterated

Needham

Buy

$109 → $204

Jun-19-18

Reiterated

H.C. Wainwright

Buy

$96 → $267

May-18-18

Reiterated

Goldman

Buy

$84 → $127

May-11-18

Upgrade

Barclays

Equal Weight → Overweight

$55 → $107

May-07-18

Reiterated

Needham

Buy

$75 → $109

May-07-18

Reiterated

H.C. Wainwright

Buy

$90 → $96

Jun-02-20 08:57PM	Is Sarepta Therapeutics Inc (SRPT) Going to Burn These Hedge Funds? Insider Monkey
05:00PM	Sarepta Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-29-20 06:28PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
01:50AM	Edited Transcript of SRPT earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-28-20 11:30AM	Is Sarepta Therapeutics (SRPT) Outperforming Other Medical Stocks This Year? Zacks
May-18-20 11:38AM	Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data Zacks
10:49AM	Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy Zacks
May-15-20 04:15PM	Why Sarepta Has A Leg Up On Pfizer With A Rival Gene Therapy: Analysts Investor's Business Daily +11.18%
03:37PM	Pfizer Posts Positive Data from Duchenne Muscular Dystrophy Candidate, but Still Trails Rival Sarepta Therapeutics Motley Fool
10:03AM	Sarepta Gains After Pfizer DMD Gene Therapy Data Fall Short Bloomberg
May-14-20 10:53AM	When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Turn A Profit? Simply Wall St.
May-13-20 02:56PM	Pros' Picks: The 15 Best Nasdaq Stocks You Can Buy Kiplinger
May-12-20 04:30PM	Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference GlobeNewswire
07:52AM	Sarepta Investors Buckle Up for Pfizers DMD Gene Therapy Update Bloomberg
May-11-20 07:00AM	Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases GlobeNewswire +6.12%
May-07-20 11:41AM	Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates Zacks
07:31AM	Sarepta Therapeutics (SRPT) Q1 2020 Earnings Call Transcript Motley Fool
07:19AM	Sarepta Reports Earnings Miss; But Key SRP-9001 Data Still On Track SmarterAnalyst
May-06-20 06:15PM	Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments GlobeNewswire
Apr-30-20 06:52PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-29-20 08:30AM	Sarepta Therapeutics to Announce First Quarter 2020 Financial Results and Recent Corporate Developments on May 6, 2020 GlobeNewswire
06:15AM	Sarepta Therapeutics Revives Anti-Viral Program for Covid-19 Barrons.com
Apr-28-20 08:30AM	Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19 GlobeNewswire
Apr-15-20 08:34AM	The Zacks Analyst Blog Highlights: Meritage Homes, Sarepta Therapeutics, The Clorox Company, The Hain Celestial Group and Entergy Zacks
Apr-14-20 07:29AM	5 Stocks to Win Big This Brutal Q1 Earnings Season Zacks
Apr-08-20 02:19PM	Have Insiders Been Buying Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares This Year? Simply Wall St.
06:00AM	Biotech vet Gilman's startup earns $190M-plus in Roche deal American City Business Journals
Mar-31-20 06:06PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-27-20 11:31AM	Sarepta Therapeutics (SRPT) Down 8% Since Last Earnings Report: Can It Rebound? Zacks
Mar-24-20 02:20AM	Edited Transcript of SRPT earnings conference call or presentation 26-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-11-20 07:57PM	Do Hedge Funds Love Sarepta Therapeutics Inc (SRPT)? Insider Monkey -6.84%
Feb-28-20 06:20PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.32%
12:10PM	Sarepta Therapeutics, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Feb-27-20 10:47AM	Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates Zacks -5.25%
08:30AM	Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program GlobeNewswire
Feb-26-20 06:15PM	Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Feb-19-20 12:31PM	Analysts Estimate Sarepta Therapeutics (SRPT) to Report a Decline in Earnings: What to Look Out for Zacks
08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on February 26, 2020 GlobeNewswire
Feb-18-20 08:33AM	Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry? Simply Wall St.
Feb-10-20 02:09PM	Shareholder Alert: Robbins LLP Reminds Investors Sarepta Therapeutics, Inc. (SRPT) Sued for Misleading Shareholders Business Wire
Feb-04-20 11:28AM	Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter GuruFocus.com +5.05%
Feb-03-20 03:31AM	BTIG: New Data Could Propel These 3 Biotech Stocks Higher in 2020 TipRanks
Jan-31-20 06:16PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
05:00AM	Families of rare-disease patients take on drug development, but face uphill battle American City Business Journals
Jan-30-20 07:19AM	Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs Zacks
Jan-28-20 02:36PM	5 'Strong Buy' Biotech Stocks to Buy for 2020 Kiplinger +5.65%
Jan-23-20 05:15PM	Biotech Hits Two-Day Skid After FDA Sheds Light On Initial Drug Rejection Investor's Business Daily
02:25PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Cardinal Health, CURO Group, Sarepta, and PG&E Corporation and Encourages Investors to Contact the Firm GlobeNewswire
Jan-22-20 11:48AM	New FDA documents shed light on agency's rejection of Sarepta drug American City Business Journals
Jan-20-20 08:54AM	Are Options Traders Betting on a Big Move in Sarepta (SRPT) Stock? Zacks
Jan-16-20 01:10PM	FDA Risks Sacrificing Its Standards for Speed Bloomberg
Jan-13-20 01:56PM	Does Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Pay Matter? Simply Wall St.
08:30AM	Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors GlobeNewswire
Jan-10-20 10:08AM	Applied Genetic Stock Up on Favorable Eye Therapy Study Data Zacks
Jan-09-20 09:12PM	Shareholder Alert: Robbins LLP Announces Sarepta Therapeutics, Inc. (SRPT) Sued for Misleading Shareholders Business Wire
Jan-06-20 08:30AM	Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-19 06:06PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-26-19 11:10AM	How Did Sarepta Therapeutics Inc (SRPT) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Dec-24-19 12:15PM	Biotech Leading in Q4: Best ETFs & Stocks Zacks
11:10AM	Gene therapy invented at Nationwide Children's lands $1.1B commercialization deal for Boston biotech American City Business Journals
09:15AM	Analysts: Roche Partnership Derisks Sarepta Investor Concerns Benzinga
09:04AM	Company News For Dec 24, 2019 Zacks
08:57AM	Sarepta (SRPT) Looks Good: Stock Adds 7.5% in Session Zacks
07:30AM	10 Biotech M&A Targets Under The Scanner For 2020 Benzinga
Dec-23-19 04:22PM	Sarepta Unveils $1.15 Billion Gene Therapy Deal And Stock Pops Investor's Business Daily +7.46%
01:15PM	Sarepta, Roche Strike Gene Therapy Licensing Agreement Worth Up To $2.85B Benzinga
10:11AM	Sarepta Signs Gene Therapy Agreement With Roche for $1.15B Zacks
08:48AM	Sarepta Stock Is Soaring on $1 Billion Deal With Roche Barrons.com
08:44AM	Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 23, 2019: SRPT, ROK, CNSL, DPW, XFOR Benzinga
01:15AM	Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal Reuters
01:00AM	Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001 GlobeNewswire
Dec-19-19 10:27AM	One particular field of drug development could dominate M&A in 2020 American City Business Journals
Dec-18-19 08:38AM	Solid Biosciences stock are up on DMD study news MarketWatch
Dec-16-19 06:04PM	This Looks Like Just the Beginning for Sarepta Therapeutics (SRPT) Stock TipRanks
04:09PM	Why This Biotech's 55% Plunge Will Ultimately Benefit Its Biggest Rival Investor's Business Daily
09:27AM	Cambridge biotech's stock price tumbles on Duchenne drug failure American City Business Journals
Dec-13-19 04:11PM	Sarepta Rockets On Stunning Reversal For Previously Rejected Drug Investor's Business Daily +31.43%
12:22PM	Sareptas surprise FDA approval for rare disease drug excites investors MarketWatch
10:13AM	FDA approves Sarepta's muscular dystrophy drug Yahoo Finance Video
09:00AM	Sarepta Stock Is Spiking as FDA Reverses Course, Approving Drug Barrons.com
08:55AM	Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up Zacks
08:30AM	Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing GlobeNewswire
08:10AM	The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer Benzinga
04:36AM	Sarepta Therapeutics Surges on FDA Approval of Muscular Dystrophy Treatment TheStreet.com
Dec-12-19 09:28PM	In an about face, FDA approves Sarepta's 2nd Duchenne drug American City Business Journals
06:43PM	Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drug MarketWatch
06:19PM	Sarepta Therapeutics Announces FDA Approval of VYONDYS 53 (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 GlobeNewswire
Dec-10-19 09:21AM	Why Is Sarepta Therapeutics (SRPT) Up 17.2% Since Last Earnings Report? Zacks
07:00AM	Biotech accelerator teams with investment firm for $210M fund raise American City Business Journals
Dec-06-19 09:33AM	The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics Zacks
Dec-05-19 04:32PM	Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
09:37AM	4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
Dec-04-19 08:33PM	Did Hedge Funds Drop The Ball On Sarepta Therapeutics Inc (SRPT) ? Insider Monkey
Dec-03-19 11:53AM	The Gene Therapy Names Moving On The Audentes Buyout Deal Benzinga
10:19AM	Breakeven On The Horizon For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Simply Wall St.
Nov-29-19 06:00PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-26-19 12:20PM	Why Did Farallon Capital Get Out of These 3 Biotech Stocks? TipRanks
Nov-15-19 08:57AM	Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal Zacks

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; and the Dyno Therapeutics, Inc. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wigzell Hans Lennart Rudolf	Director	May 20	Option Exercise	10.08	5,000	50,400	18,792	May 22 08:00 PM
Wigzell Hans Lennart Rudolf	Director	May 20	Sale	150.64	5,000	753,210	13,792	May 22 08:00 PM
Barry Richard	Director	May 15	Sale	141.26	30,000	4,237,946	3,159,140	May 15 09:02 PM
Wigzell Hans Lennart Rudolf	Director	Mar 04	Option Exercise	8.46	5,000	42,300	18,792	Mar 06 08:01 PM
Wigzell Hans Lennart Rudolf	Director	Mar 04	Sale	116.89	5,000	584,450	13,792	Mar 06 08:01 PM
Mahatme Sandesh	EVP, CFO & CBO	Dec 13	Option Exercise	28.88	125,000	3,610,443	155,179	Dec 17 08:00 PM
Howton David T	EVP, General Counsel	Dec 13	Option Exercise	21.48	78,000	1,675,439	103,171	Dec 17 08:01 PM
Cumbo Alexander	EVP, Chief Commercial Officer	Dec 13	Option Exercise	23.70	32,706	775,232	43,867	Dec 17 08:02 PM
Cumbo Alexander	EVP, Chief Commercial Officer	Dec 13	Sale	125.50	42,000	5,271,000	1,867	Dec 17 08:02 PM
Howton David T	EVP, General Counsel	Dec 13	Sale	125.50	78,000	9,789,000	25,171	Dec 17 08:01 PM
Mahatme Sandesh	EVP, CFO & CBO	Dec 13	Sale	125.50	125,000	15,687,500	30,179	Dec 17 08:00 PM
Howton David T	EVP, General Counsel	Nov 22	Option Exercise	16.13	34,272	552,667	36,993	Nov 26 08:01 PM
Howton David T	EVP, General Counsel	Nov 22	Sale	105.00	25,000	2,625,000	11,993	Nov 26 08:01 PM
Barry Richard	Director	Sep 13	Buy	87.49	3,309	289,504	3,187,065	Sep 16 08:00 AM
Barry Richard	Director	Sep 12	Buy	87.49	1,691	147,950	3,183,756	Sep 16 08:00 AM
BONNEY MICHAEL W	Director	Sep 09	Buy	86.74	2,000	173,480	7,051	Sep 09 02:18 PM
BEHRENS M KATHLEEN	Director	Sep 06	Buy	87.98	2,500	219,950	125,667	Sep 06 02:13 PM
BEHRENS M KATHLEEN	Director	Sep 05	Option Exercise	7.80	5,000	39,000	123,167	Sep 06 02:13 PM
Mahatme Sandesh	EVP, CFO & CBO	Aug 21	Option Exercise	23.85	100,000	2,385,000	130,179	Aug 22 07:20 PM
Barry Richard	Director	Aug 20	Buy	99.32	5,000	496,593	3,182,065	Aug 20 05:43 PM
Mahatme Sandesh	EVP, CFO & CBO	Aug 15	Option Exercise	24.73	9,754	241,232	30,179	Aug 15 04:33 PM
Barry Richard	Director	Aug 14	Buy	122.50	3,700	453,250	3,177,065	Aug 14 04:38 PM
Barry Richard	Director	Aug 12	Buy	122.50	1,300	159,250	3,173,365	Aug 13 04:31 PM
INGRAM DOUGLAS S	President & CEO	Aug 12	Buy	123.07	16,252	2,000,160	432,197	Aug 12 05:48 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience